Recommendations for follow-up care of individuals with an inherited predisposition to cancer .1. Hereditary nonpolyposis colon cancer

被引:370
作者
Burke, W
Petersen, G
Lynch, P
Botkin, J
Daly, M
Garber, J
Kahn, MJE
McTiernan, A
Offit, K
Thomson, E
Varricchio, C
机构
[1] JOHNS HOPKINS UNIV,DEPT EPIDEMIOL,BALTIMORE,MD
[2] UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX
[3] UNIV UTAH,UTAH CTR HUMAN GENOME RES,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT
[4] FOX CHASE CANC CTR,PHILADELPHIA,PA 19111
[5] DANA FARBER CANC INST,BOSTON,MA 02115
[6] NATL BREAST CANC COALIT,SEATTLE,WA
[7] FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104
[8] MEM SLOAN KETTERING INST CANC RES,NEW YORK,NY
[9] NATL HUMAN GENOME RES INST,ETH LEGAL & SOCIAL IMPLICAT BRANCH,BETHESDA,MD
[10] NCI,BETHESDA,MD 20892
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1997年 / 277卷 / 11期
关键词
D O I
10.1001/jama.277.11.915
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations associated with hereditary nonpolyposis colon cancer (HNPCC). Participants.-A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by the National Human Genome Research Institute (previously the National Center for Human Genome Research). Evidence.-Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to colon cancer were identified using MEDLINE and bibliographies of articles thus identified, Indexing terms used were ''genetics'' in combination with ''colon cancer,'' and ''screening'' in combination with ''cancer family'' and ''HNPCC,'' For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. Consensus Process.-The task force developed recommendations through discussions over a 14-month period. Conclusions.-Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown, Based on observational studies, colonoscopy every 1 to 3 years starting at age 25 years is recommended for individuals known to have HNPCC-associated mutations, Endometrial cancer screening is also recommended, based on expert opinion concerning presumptive benefit, No recommendation is made for or against prophylactic surgery (ie, colectomy, hysterectomy); these surgeries are an option for mutation carriers, but evidence of benefit is lacking, It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.
引用
收藏
页码:915 / 919
页数:5
相关论文
共 54 条
  • [1] Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome
    Aarnio, M
    Mecklin, JP
    Aaltonen, LA
    NystromLahti, M
    Jarvinen, HJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (06) : 430 - 433
  • [2] AGGRESSIVE POLYPS IN HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER - TARGETS FOR SCREENING
    AHLQUIST, DA
    [J]. GASTROENTEROLOGY, 1995, 108 (05) : 1590 - 1592
  • [3] [Anonymous], 1996, GUID CLIN PREV SERV
  • [4] AVERETTE HE, 1993, CANCER, V72, P1043, DOI 10.1002/1097-0142(19930801)72:3+<1043::AID-CNCR2820721317>3.0.CO
  • [5] 2-E
  • [6] OUTPATIENT ENDOMETRIAL SAMPLING WITH THE PIPELLE CURETTE
    BENBARUCH, G
    SEIDMAN, DS
    SCHIFF, E
    MORAN, O
    MENCZER, J
    [J]. GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1994, 37 (04) : 260 - 262
  • [7] SHOULD RELATIVES OF PATIENTS WITH COLORECTAL-CANCER BE SCREENED - A CRITICAL-REVIEW OF THE LITERATURE
    BREWER, DA
    FUNG, CLS
    CHAPUIS, PH
    BOKEY, EL
    [J]. DISEASES OF THE COLON & RECTUM, 1994, 37 (12) : 1328 - 1338
  • [8] BURKE W, IN PRESS JAMA
  • [9] FITZGIBBONS RJ, 1990, HEREDITARY COLORECTA, P211
  • [10] FRIEDLANDER M, 1992, CURR OPIN ONCOL, V4, P918